meperidine hydrochloride - Profile

What are the generic sources for meperidine hydrochloride and what is the scope of patent protection?

Meperidine hydrochloride is the generic ingredient in four branded drugs marketed by Hospira, Quagen, Abbott, Baxter Hlthcare, Igi Labs Inc, Intl Medication, Parke Davis, Watson Labs, West-ward Pharms Int, Icu Medical Inc, Specgx Llc, Hikma, Barr, Duramed Pharms Barr, Epic Pharma Llc, Genus, Strides Pharma Intl, Sun Pharm Inds Inc, Sun Pharm Industries, and Wyeth Ayerst, and is included in forty-five NDAs. Additional information is available in the individual branded drug profile pages.

Summary for meperidine hydrochloride

US Patents:	0
Tradenames:	4
Applicants:	20
NDAs:	45

US Patents and Regulatory Information for meperidine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira	DEMEROL	meperidine hydrochloride	INJECTABLE;INJECTION	021171-001	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes
Hospira	DEMEROL	meperidine hydrochloride	INJECTABLE;INJECTION	021171-002	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes
Hospira	DEMEROL	meperidine hydrochloride	INJECTABLE;INJECTION	021171-003	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes
Hospira	DEMEROL	meperidine hydrochloride	INJECTABLE;INJECTION	021171-004	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes
Quagen	DEMEROL	meperidine hydrochloride	INJECTABLE;INJECTION	005010-007	Approved Prior to Jan 1, 1982		DISCN	No	No

Meperidine Hydrochloride: Investment and Fundamentals Analysis

Last updated: February 19, 2026

Meperidine hydrochloride, an opioid analgesic, presents a complex investment profile influenced by its established therapeutic use, evolving regulatory landscape, and the persistent challenges of opioid abuse. The drug's patent landscape is largely expired, allowing for generic competition, which significantly impacts pricing and market share. Investment opportunities are therefore more likely to lie in process innovation, novel formulations, or niche therapeutic applications rather than first-generation market exclusivity.

What are the Current Market Dynamics for Meperidine Hydrochloride?

The market for meperidine hydrochloride is characterized by a mature, genericized product. The primary driver of demand remains its efficacy as a short-term analgesic for moderate to severe pain, particularly in post-operative settings and for certain types of chronic pain. However, its use has been tempered by significant concerns regarding its abuse potential and the risk of respiratory depression, leading to stricter prescribing guidelines and reduced utilization in favor of alternative analgesics, including non-opioid options and newer opioid formulations with potentially lower abuse liabilities.

Key Market Factors:

• Generic Competition: The expiration of primary patents has led to widespread generic availability, driving down prices and limiting profit margins for individual manufacturers. The market is fragmented with multiple generic suppliers.
• Therapeutic Niche: Meperidine hydrochloride maintains a role in specific clinical scenarios where its pharmacokinetic profile or particular side effect profile may be deemed advantageous by prescribers. This includes situations like post-operative pain management and certain types of colic.
• Regulatory Scrutiny: As a Schedule II controlled substance in the United States, meperidine hydrochloride is subject to rigorous regulatory oversight by the Drug Enforcement Administration (DEA) and the Food and Drug Administration (FDA). This includes strict quotas on manufacturing, dispensing limitations, and monitoring for diversion and abuse.
• Opioid Crisis Impact: The ongoing opioid crisis has led to increased public and regulatory pressure to reduce opioid prescribing. This has indirectly impacted meperidine hydrochloride's market by encouraging the adoption of pain management strategies that minimize opioid use.
• Availability of Alternatives: A growing array of alternative analgesics, including non-opioid medications (NSAIDs, acetaminophen, gabapentinoids, antidepressants), topical agents, and other opioid classes with different risk profiles, compete with meperidine hydrochloride.

What is the Patent Landscape for Meperidine Hydrochloride?

Meperidine hydrochloride (marketed under brand names such as Demerol) was first patented in the mid-20th century. The original composition of matter patents have long expired, along with patents on its initial manufacturing processes and formulations.

Patent Expiration Timeline:

• Original Composition of Matter Patents: Expired in the late 20th century.
• Process Patents: Many early process patents have also expired.
• Formulation and Delivery Patents: While less common for established drugs, any patents related to novel formulations, extended-release mechanisms, or specific delivery devices for meperidine hydrochloride would have their own expiration dates. However, significant innovation in this area for meperidine hydrochloride is limited, given its history and the availability of newer drug classes.
• Orphan Drug Exclusivity: There is no indication of meperidine hydrochloride being granted orphan drug status for any indication, thus no related exclusivity periods apply.
• Pediatric Exclusivity: While pediatric studies may have been conducted, they do not typically grant market exclusivity in the same manner as new chemical entity (NCE) patents.

Current Patent Status:

The absence of robust, expiring patent protection for meperidine hydrochloride means that the market is characterized by generic competition. Any new patent activity would likely focus on:

• Novel Manufacturing Processes: Patents for more efficient, cost-effective, or environmentally friendly synthesis routes.
• New Indications: If a novel therapeutic use for meperidine hydrochloride were discovered and proven, it could potentially lead to new patent protection for that specific use. This is a low probability given the drug's known risks and the development of targeted therapies.
• Combination Therapies: Patents for formulations combining meperidine hydrochloride with other active pharmaceutical ingredients for synergistic effects or to mitigate side effects.
• Abuse Deterrent Formulations (ADFs): While ADFs have been a focus for other opioids, development for meperidine hydrochloride is less common, likely due to the drug’s established risk profile and the availability of newer, more advanced ADFs in other opioid classes.

The lack of a strong, active patent portfolio for meperidine hydrochloride limits direct investment in new patent filings and emphasizes the importance of manufacturing efficiency and market access for competing generic producers.

What are the Regulatory Considerations for Meperidine Hydrochloride?

Meperidine hydrochloride is subject to extensive and evolving regulatory controls due to its opioid nature and potential for abuse. These regulations significantly influence manufacturing, distribution, prescribing, and ultimately, market access and profitability.

Key Regulatory Bodies and Frameworks:

• Drug Enforcement Administration (DEA): Meperidine hydrochloride is classified as a Schedule II controlled substance under the Controlled Substances Act (CSA) in the United States. This classification signifies a high potential for abuse, with use currently accepted for medical purposes under severe restrictions.
  • Manufacturing Quotas: The DEA sets annual aggregate production quotas (APQs) for Schedule II substances. These quotas limit the total amount of meperidine hydrochloride that can be manufactured in the U.S. each year, directly impacting supply and potentially price. Manufacturers must apply for and be granted specific quota allocations.
  • Registration and Security: Manufacturers, distributors, pharmacies, and practitioners handling meperidine hydrochloride must register with the DEA and comply with strict security requirements to prevent diversion.
  • Record Keeping and Reporting: Detailed records of all transactions, dispensing, and inventory must be maintained and reported to the DEA.
• Food and Drug Administration (FDA): The FDA regulates the safety and efficacy of drugs.
  • Prescribing Information (PI): The FDA mandates specific warnings and precautions on the drug's label, including boxed warnings (black box warnings) regarding the risks of addiction, abuse, and misuse, life-threatening respiratory depression, and accidental overdose.
  • Risk Evaluation and Mitigation Strategies (REMS): While specific REMS programs for meperidine hydrochloride may not be as extensive as for some newer opioids, the overall regulatory framework for opioid prescribing, including physician education and patient counseling, applies.
  • Manufacturing Standards (cGMP): Manufacturers must adhere to current Good Manufacturing Practices (cGMP) to ensure product quality, purity, and consistency.
• State-Level Regulations: Individual states often have additional regulations regarding controlled substances, including prescription drug monitoring programs (PDMPs) that track the dispensing of controlled substances to identify and prevent potential abuse and doctor shopping.

Impact of Regulations on Investment:

• Increased Compliance Costs: Adhering to DEA and FDA regulations incurs significant operational and compliance costs for manufacturers, including enhanced security, detailed record-keeping, and specialized personnel.
• Supply Chain Controls: Quotas and strict distribution controls can create supply chain challenges and affect the ability of companies to scale production rapidly.
• Prescribing Limitations: Regulatory efforts to curb opioid use, including stricter prescribing guidelines and the promotion of alternatives, directly reduce the overall demand for meperidine hydrochloride.
• Liability Risk: Companies involved in the manufacturing and distribution of opioids face significant legal and financial risks related to product liability lawsuits stemming from opioid addiction and overdose.

What are the Potential Investment Avenues for Meperidine Hydrochloride?

Given the mature, genericized nature of meperidine hydrochloride and the restrictive regulatory environment, direct investment in companies solely focused on its manufacture for broad market use offers limited upside. Investment opportunities are more likely to arise from specialized manufacturing capabilities, process optimization, or niche market access.

Potential Investment Scenarios:

1. Generic Manufacturing with Optimized Processes:

   • Focus: Companies that have developed highly efficient, low-cost manufacturing processes for meperidine hydrochloride. This would involve patents on novel synthesis routes, improved purification techniques, or significant economies of scale in production.
   • Rationale: In a price-sensitive generic market, superior manufacturing efficiency can provide a competitive advantage and sustain profitability.
   • Risk: Dependence on a single, older drug with declining usage and intense price competition. Regulatory quota limitations can cap production volumes.

2. Specialty Chemical Suppliers to Generic Manufacturers:

   • Focus: Companies that supply critical, high-purity raw materials or intermediates essential for meperidine hydrochloride synthesis.
   • Rationale: Demand for these components is tied to the production volumes of meperidine hydrochloride. A reliable supply chain for these precursors can be valuable.
   • Risk: The demand is indirectly linked to the declining broader market for meperidine hydrochloride. The success of such a company is contingent on the continued, albeit reduced, demand for the final drug product.

3. Contract Manufacturing Organizations (CMOs) with Controlled Substance Expertise:

   • Focus: CMOs that possess the necessary DEA registrations, security infrastructure, and regulatory compliance expertise to manufacture Schedule II controlled substances like meperidine hydrochloride for multiple generic clients.
   • Rationale: The high barrier to entry for controlled substance manufacturing means that specialized CMOs can secure contracts from companies lacking in-house capabilities or quota allocations.
   • Risk: Reliance on the aggregate demand for meperidine hydrochloride and the potential for clients to consolidate or exit the market.

4. Development of Novel Formulations (Low Probability):

   • Focus: While unlikely for meperidine hydrochloride given its risk profile, any company that could develop a truly novel, abuse-deterrent formulation or a long-acting delivery system that significantly mitigates risks while retaining efficacy could generate new patent protection and market differentiation.
   • Rationale: Such an innovation could create a distinct product with potential for higher margins and re-entry into markets where standard meperidine hydrochloride use has declined.
   • Risk: High R&D costs, regulatory hurdles for novel formulations, and the challenge of overcoming the inherent risks associated with the meperidine molecule itself.

Considerations for Due Diligence:

• DEA Quota History: Analyze a company's historical DEA quota allocations and their ability to secure future quotas.
• Manufacturing Efficiency: Assess the cost structure and technological advantages of manufacturing processes.
• Regulatory Compliance: Evaluate the robustness of a company's compliance programs and their track record with regulatory bodies.
• Market Share and Sales Trends: While overall market decline is expected, analyze the specific market share and sales trends for the company's meperidine hydrochloride product.
• Diversification: Determine if the company has diversified revenue streams beyond meperidine hydrochloride to mitigate risks associated with opioid market contraction.

Key Takeaways

Meperidine hydrochloride is a mature, genericized opioid analgesic whose market is constrained by declining overall opioid use, intense generic competition, and stringent regulatory controls. Direct investment in its broad production is challenging due to low margins and regulatory barriers. Opportunities are more probable in specialized manufacturing, process optimization, and controlled substance handling expertise within the contract manufacturing sector.

FAQs

• What is the primary market application for meperidine hydrochloride today? Meperidine hydrochloride is primarily used for short-term management of moderate to severe pain, particularly in post-operative settings and for specific types of pain like colic, where its pharmacokinetic profile may be deemed suitable by clinicians.

• What are the main regulatory challenges facing meperidine hydrochloride manufacturers? Manufacturers face significant challenges including DEA manufacturing quotas limiting supply, strict security and record-keeping requirements, and the overall regulatory pressure to reduce opioid prescribing due to abuse and overdose risks.

• Are there any significant patents protecting meperidine hydrochloride formulations? Original composition of matter and process patents for meperidine hydrochloride have long expired. Any existing patents are likely to be on niche manufacturing improvements or specific, less common formulations, but no broad patent protection exists for the core drug.

• What is the impact of the ongoing opioid crisis on meperidine hydrochloride investment? The opioid crisis has led to increased scrutiny and restrictions on all opioids, including meperidine hydrochloride. This translates to reduced prescribing, lower demand, and greater regulatory and liability risks, making broad market investment less attractive.

• What type of companies are best positioned to profit from meperidine hydrochloride production? Companies best positioned are those with highly efficient, low-cost generic manufacturing capabilities, strong expertise in DEA-regulated controlled substance handling, or those operating as contract manufacturers for other generic drug companies.

---

Cited Sources

[1] U.S. Drug Enforcement Administration. (n.d.). Controlled Substances Act. Retrieved from [DEA website] (Specific URL for CSA would be used if available and static).

[2] U.S. Food and Drug Administration. (n.d.). Controlled Substances and Abuse. Retrieved from [FDA website] (Specific URL for relevant FDA guidance on controlled substances would be used if available and static).

[3] U.S. Food and Drug Administration. (n.d.). Labeling of Opioid Analgesics. Retrieved from [FDA website] (Specific URL for boxed warning guidance would be used if available and static).